Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”This is worrying.
The Tribune newspaper in India is reporting that authorities have asked for the immediate suspension of use (and quarantining) of six batches of plasma derived factor IX concentrate for use in haemophilia B.
The products are made by a company called ICHOR Biologics, a company I have not heard of before.
The article is missing two critical pieces of information:
a) What is the adverse event that led to the suspension of this product
b) How many patients are affected. Only the total number of patients in the region are given.
I really hope this is not new transmission of a viral infection in persons with haemophilia.
The story may be a local one in Punjab in India, but the international world of haemophilia will be following this story.”
Read The Tribune article here.
Stay updated on the emerging with Hemostasis Today.
-
Aug 29, 2026, 17:05What If Factor XI inhibition Could Reshape the Future of Anticoagulation – ISTH
-
Aug 29, 2026, 16:44Nipocalimab for Warm Autoimmune Hemolytic Anemia: What the FDA Approval Means
-
Aug 29, 2026, 16:17The Future of Bleeding Disorder Research is Getting Bigger – Global Hemophilia Report
-
Aug 29, 2026, 16:03Marco De Giovanni: The Platelet – Serotonin Link Behind Severe COVID-19
-
Aug 29, 2026, 16:01FDA Approves Imaavy for wAIHA – Thalassaemia International Federation
-
Aug 29, 2026, 16:00Dianne E. van der Wal: Advancing Platelet Research at ISTH 2026 in Paris
-
Aug 29, 2026, 15:55Cory Dugan: Iron Deficiency and Anemia Across the Female Life
-
Aug 29, 2026, 15:53Melina Rodriguez: FDA Approves Imaavy as First Treatment for Warm AIHA
-
Aug 29, 2026, 15:50Karen T․: Seeking a Patient Liaison to Support the Bleeding Disorders Community